Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin J Edelman

Showing results (11-20 of 186) with videos related to

Pageof 19
Sort By:
Clinical Lung Cancer|October 28, 2005
The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancerMartin J Edelman
Lung Cancer (Amsterdam, Netherlands)|November 15, 2002
Past, present, and future of gemcitabine and carboplatin regimens in advanced non-small cell lung cancerMartin J Edelman
Expert Review of Anticancer Therapy|May 2, 2003
Taking stock of targeted therapy in cancer: rational expectations or irrational exuberance?Martin J Edelman
JAMA Oncology|November 5, 2016
Highlights in the Treatment of Lung Cancer: What's New? Not MuchMartin J Edelman
Expert Opinion on Pharmacotherapy|June 5, 2003
Neoadjuvant chemotherapy and chemoradiotherapy for non-small cell lung cancer: current status and future prospectsMartin J Edelman
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Novel cytotoxic agents for non-small cell lung cancerMartin J Edelman
JAMA Network Open|June 9, 2020
Biomarker Testing in Lung Cancer-What Does It Mean?Hossein Borghaei, Martin J Edelman
Current Treatment Options in Oncology|January 15, 2003
Treatment options for brain metastases in patients with non-small cell lung cancerSadaf Taimur, Martin J Edelman
Clinical Lung Cancer|December 3, 2011
Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistanceMartin J Edelman, Marianna Shvartsbeyn
Translational Lung Cancer Research|March 26, 2015
Resistance to anti-angiogenic agents: a brief review of mechanisms and consequencesMartin J Edelman, Li Mao
Pageof 19

Showing results (11-20 of 186) with videos related to

Sort By:
Pageof 19
Clinical Lung Cancer|October 28, 2005
The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancerMartin J Edelman
Lung Cancer (Amsterdam, Netherlands)|November 15, 2002
Past, present, and future of gemcitabine and carboplatin regimens in advanced non-small cell lung cancerMartin J Edelman
Expert Review of Anticancer Therapy|May 2, 2003
Taking stock of targeted therapy in cancer: rational expectations or irrational exuberance?Martin J Edelman
JAMA Oncology|November 5, 2016
Highlights in the Treatment of Lung Cancer: What's New? Not MuchMartin J Edelman
Expert Opinion on Pharmacotherapy|June 5, 2003
Neoadjuvant chemotherapy and chemoradiotherapy for non-small cell lung cancer: current status and future prospectsMartin J Edelman
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Novel cytotoxic agents for non-small cell lung cancerMartin J Edelman
JAMA Network Open|June 9, 2020
Biomarker Testing in Lung Cancer-What Does It Mean?Hossein Borghaei, Martin J Edelman
Current Treatment Options in Oncology|January 15, 2003
Treatment options for brain metastases in patients with non-small cell lung cancerSadaf Taimur, Martin J Edelman
Clinical Lung Cancer|December 3, 2011
Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistanceMartin J Edelman, Marianna Shvartsbeyn
Translational Lung Cancer Research|March 26, 2015
Resistance to anti-angiogenic agents: a brief review of mechanisms and consequencesMartin J Edelman, Li Mao
Pageof 19